Why Corcept Therapeutics Incorporated (CORT) stock moved
Updated Nov 4, 2026
Corcept Therapeutics Incorporated (CORT) shares rose 1.8% to $81.93 as of November 4, 2026, a modest gain from the prior close of $80.46. BestStocks flagged the session as a major change for CORT. The move is tied to an earnings beat. Below, we break down what changed for CORT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Earnings Beat
Corcept Therapeutics Incorporated (CORT) reported EPS of $1.01 vs. consensus estimate of $0.79, beating by 27.2% on November 3, 2026. Monitor CORT's next quarterly earnings report and any guidance updates on sales trends for its Cushing's syndrome franchise.
This summary describes the catalyst and move as first detected on Nov 3, 2026, 4:38 PM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsMedium confidence
Rel. volume
1.3×
Normal
Vs peers
—
No comparable peers
Market cap
$8.9B
NASDAQ Capital Market
Analyst target
$133
+62.1% vs price
Price chart
Nov 3
Not enough price data.
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Corcept Therapeutics Incorporated investors
For Corcept Therapeutics Incorporated investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Positive 1.8% session move. Weighing against that: Corcept Therapeutics Incorporated (CORT) moved -6.51% from $91.88 to $85.90 on 2026-07-13; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $132.80, implying +62.1% upside from $81.93. BestStocks rates the overall signal quality medium (60/100). With earnings roughly 118 days out, the next report is the most likely near-term test of the move.
CORT price reaction
CORT last traded at $81.93, up $1.47 (+1.83%) from the previous close of $80.46. The session traded on 1.3× average volume (normal), so participation was unremarkable.
Bullish and bearish analyst opinions on Corcept Therapeutics Incorporated (CORT)
▲Latest catalyst·strengthens the bull case
The latest catalyst — an earnings beat the market rewarded — it strengthens the bull case and confirms the prevailing bullish analyst lean.
The consensus analyst price target on Corcept Therapeutics Incorporated (CORT) is $132.80, 62.1% above the recent $81.93. Over the past 90 days analysts logged 0 upgrades, 1 maintain, and 0 downgrades. Here is how the bullish and bearish cases on CORT line up.
▲ The bullish case
+Wall Street's consensus price target of $132.80 implies +62.1% upside from $81.93.
+The Street's most bullish target is $165.00 (+101.4%).
+Earnings beat with positive market reaction.
+Positive 1.8% session move.
+Corcept Therapeutics surged +28.40% to $119.35 after filing an earnings report and material event (8-K) today, per SEC filings and FMP data.
▼ The bearish case
−The most bearish analyst target is $50.00 (-39.0%).
−Corcept Therapeutics Incorporated (CORT) moved -6.51% from $91.88 to $85.90 on 2026-07-13.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
The latest catalyst moved the balance toward the bulls — the hollow tick marks where it sat before.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 3, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Corcept Therapeutics Incorporated (CORT) filed a new 10-Q on 2026-11-03, with earnings scheduled for 2026-11-04 against a consensus EPS estimate of $0.79.
News2026-10-26
Corcept announced positive Phase 2 results for Lifyorli combined with chemotherapy in platinum-resistant ovarian cancer.
Corcept Therapeutics fell 18.19% to $87.95 after a competitor milestone threatened its recently FDA-approved drug Lifyorli. Genmab A/S reported successful Phase 3 trial data for rinatabart sesutecan (Rina-S) in platinum-resistant ovarian cancer, the same indication Lifyorli targets. Pre-earnings profit-taking ahead of Q3 results amplified the selloff; volume reached 2.81x the time-adjusted average, underscoring conviction in the move.
Material / Earnings2026-10-22
Corcept Therapeutics Incorporated (CORT) moved -6.65% from $115.16 to $107.50 on 2026-10-22. We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move appears driven by broad valuation pullbacks and lingering investor caution tied to earlier regulatory setbacks, with the stock reaching a new 30-day low on near-average volume.
News2026-10-20
2026 ADA/EASD Consensus Report recommends screening for hypercortisolism in difficult-to-control Type 2 Diabetes patients.
Corcept Therapeutics rose 3.13% to $122.25, driven by sustained institutional buying and strong Q2 2026 fundamentals. New institutional positions (including Vilga Financial Planning's 13,046-share acquisition) and raised full-year guidance to a $1.15 billion midpoint are fueling momentum, according to recent SEC filings and the company's earnings report showing 31.7% year-over-year revenue growth to $256.1 million. Volume remained below average at 0.19x expected levels 310 minutes into the session.
Corcept Therapeutics shares rose 3.02% to $119.74, building on positive momentum from strong Q2 commercial execution and raised full-year revenue guidance of $1.1–$1.2 billion, according to the Zacks Analyst Blog and Yahoo Finance. The move also reflects market confidence following the October 1 leadership transition, with Justin Gunn taking over as President of the Endocrinology division. Volume remained below average at 0.28x expected for this point in the session.
Material / Earnings2026-09-24
CORT moved +5.94% from its $111.86 open to a $118.51 close on 2026-09-24.
Upcoming catalysts & outlook
Next earnings
2027-03-02 (est.)
in 118 days
Earnings Release
2027-03-02
High impact
Thesis shift
Bullish Shift
bullish signal
Risk level
Medium
from change events
Frequently asked questions about CORT
Why did Corcept Therapeutics Incorporated (CORT) stock move?
CORT rose 1.8% to $81.93. The move is associated with an earnings beat.
How much did CORT stock rise?
CORT gained 1.83% ($1.47) versus the prior close of $80.46, last trading at $81.93 on 1.3× average volume.
When is Corcept Therapeutics Incorporated's next earnings date?
CORT's next earnings report is estimated for 2027-03-02 — about 118 days away.
What is the analyst price target for CORT?
The consensus analyst price target for CORT is $132.80, about 62.1% above the current $81.93. Over the past 90 days, analysts recorded 0 upgrades, 1 maintain, and 0 downgrades.
How BestStocks tracks CORT
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 20 tracked change events for CORT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 4, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
